QUOTE AND NEWS
PR Newswire  Nov 24  Comment 
NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being
StreetInsider.com  Nov 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AEterna+Zentaris+%28AEZS%29+Reports+That+Perifosine+Partner+Keryx+Biopharma+%28KERX%29+Will+Prersent+Data+from+Phase+12+at+51st+ASH+Meeting/5097291.html for the full story.
StreetInsider.com  Nov 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Keryx+Biopharma+%28KERX%29+Posts+Q3+EPS+of+1c%2C+Beats+by+10c/5092381.html for the full story.
PR Newswire  Nov 6  Comment 
NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the
PR Newswire  Nov 4  Comment 
NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit being
PR Newswire  Oct 29  Comment 
NEW YORK, Oct 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference taking
StreetInsider.com  Oct 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Keryx+Bio+%28KERX%29+Announces+Perifosine+Phase+2+for+Chronic+and+Small+Lymphocytic+Leukemia/5004186.html for the full story.
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 


 
KERX AT A GLANCE
P/E 10.9AVG
EV/EBITDA 15.9HIGH
ROA 25.7%VERY HIGH
ROE 64.3%VERY HIGH
Debt to Equity 0.300AVG
Current Ratio 5.40HIGH
Interest Coverage Ratio -6.31AVG
 
 
 
 
 
 
 
 




References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki